News Sentiment

IMRN sentiment intelligence

Immuron Ltd ADR news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 44 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.23 Week of 10 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

80/100 classification confidence.

Company focus 35

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

+11.8% over one week, +3.4% over four weeks, trend active, and below fair value.

Latest direct headline Neutral

BNY Mellon Lifts Substantial Holding in Immuron to 44.61% via ADR Program Deposits

Market Reaction

Price moving ahead of tone

65/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 80/100 classification
One-week reaction 11.8% Price confirming higher
Trend fit Trend active 3.4% over four weeks
Fair value -32.2% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 15
Neutral 26
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 35
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 8
TradingKey 6
Market source 5
Kalkine 4
markets.businessinsider.com 2
simplywall.st 2
scanx.trade 1
grafa.com 1

Event Lens

What the news is about

Classified themes
Market update 23
Earnings 12
Regulatory and legal 3
Guidance 3
Analyst action 2
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 44
Kalkine Direct company coverage

BNY Mellon Lifts Substantial Holding in Immuron to 44.61% via ADR Program Deposits

The Bank of New York Mellon Corporation (BNY) has increased its substantial holding in Immuron Limited (ASX: IMC) to 44.61% from 43.60%, through its role as depositary for Immuron's American Depositary Receipt (ADR) program. This increase, representing 3,259,720 ordinary shares,

Tone
Neutral 50/100
Event
Market update
Published
16 Jul 2026 14:42
Source
Kalkine
scanx.trade Direct company coverage

Immuron FY26 sales rise 6% to AUD$7.7 million led by Australia

Immuron Limited reported a 6% increase in global revenue to AUD$7.7 million for FY26, driven by four consecutive quarters of sales growth, primarily stemming from strong performance in Australia. Australian sales rose 10% to AUD$5.8 million, while U.S. sales grew 7% in AUD terms

Tone
Positive 71/100
Event
Earnings
Published
16 Jul 2026 10:42
Source
scanx.trade
markets.businessinsider.com Direct company coverage

Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year

Immuron Limited reported continued sales growth for Travelan® in FY26, with global sales reaching AUD$7.7 million, a 6% increase from the prior comparative period. Australia saw a 10% sales increase, driven by marketing and new store growth, while US sales increased by 7% in AUD

Tone
Neutral 50/100
Event
Market update
Published
16 Jul 2026 10:42
Source
markets.businessinsider.com
grafa.com Direct company coverage

Australia's Immuron sales reach $7.7 million in FY26

Immuron (ASX:IMC) announced global sales of $7.7 million for FY26, marking a 6% increase over the previous year. This growth was primarily driven by strong sales of Travelan in Australia and steady expansion in North America. Despite the positive sales figures, the Immuron share

Tone
Positive 64/100
Event
Market update
Published
16 Jul 2026 02:30
Source
grafa.com
Kalkine Direct company coverage

Immuron Records AUD$7.7 Million in Global Travelan® Sales for FY26, Marking Four Consecutive Quarters of Year-on-Year Growth

Immuron Limited reported unaudited global sales of AUD$7.7 million for its flagship product, Travelan®, in FY26, marking a 6% increase from the prior year and achieving four consecutive quarters of year-on-year growth. This growth was primarily driven by strong Australian sales,

Tone
Positive 80/100
Event
Market update
Published
16 Jul 2026 01:08
Source
Kalkine
Stock Titan Direct company coverage

Immuron (NASDAQ: IMRN) advances IMM-529 CDI drug with new partnering push

Immuron Limited has engaged Pullan Consulting to secure a strategic partnership for its IMM-529 program, which targets Clostridioides difficile infection (CDI). IMM-529 has FDA Investigational New Drug approval for a planned Phase 2 trial in Australia, with a projected base case

Tone
Positive 73/100
Event
Regulatory and legal
Published
06 Jul 2026 11:40
Source
Stock Titan
Kalkine Direct company coverage

Immuron Engages Pullan Consulting to Advance IMM-529 Partnering Strategy

Immuron Limited has engaged Pullan Consulting to strategically advance its investigational drug, IMM-529, designed to treat Clostridioides difficile infection (CDI). This move follows the FDA's approval of IMM-529's Investigational New Drug (IND) application, allowing for upcomin

Tone
Neutral 50/100
Event
Regulatory and legal
Published
06 Jul 2026 10:53
Source
Kalkine
markets.businessinsider.com Direct company coverage

Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategy

Immuron Limited has engaged Pullan Consulting to advance its partnering strategy for IMM-529, a treatment for Clostridioides difficile infection (CDI). The company has FDA approval for its IMM-529 Investigational New Drug application and is seeking a partner to fund clinical deve

Tone
Positive 70/100
Event
Regulatory and legal
Published
06 Jul 2026 10:40
Source
markets.businessinsider.com
Stock Titan Direct company coverage

Immuron seeks partner for gut infection drug IMM-529

Immuron (NASDAQ: IMRN, ASX: IMC) has engaged Pullan Consulting to find a strategic partner for IMM-529, its oral polyclonal antibody candidate for Clostridioides difficile infection (CDI). IMM-529 has FDA-cleared IND 32095 and is Phase 2 trial-ready, with a planned randomized, do

Tone
Positive 75/100
Event
Market update
Published
06 Jul 2026 09:40
Source
Stock Titan
Stock Titan Direct company coverage

Immuron (NASDAQ: IMRN) now has 322.8M ordinary shares on issue

Immuron Limited (NASDAQ: IMRN) has announced a change in its issued capital, with 3,805,528 ordinary fully paid shares ceasing on the ASX. Following this cessation, the company now has 322,848,081 ordinary shares on issue. This adjustment to the share count will be used by the AS

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 11:59
Source
Stock Titan
Kalkine Direct company coverage

Immuron Cancels 3.8 Million Shares at $0.032 Each Under Unmarketable Parcel Buy-Back

Immuron Limited (ASX: IMC) has completed the cancellation of 3,805,528 ordinary fully paid shares at AUD $0.032 each as part of an unmarketable parcel buy-back program, effective June 29, 2026. This move reduces the company's total quoted ordinary share count to 322,848,081 and a

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 02:41
Source
Kalkine
Investing.com India Direct company coverage

Form 6K Immuron Ltd ADR For: 23 June By Investing.com

This article reports on the filing of Form 6K by Immuron Ltd ADR for June 23rd. The content itself is very brief, consisting only of the headline repeated several times, and primarily serves as an entry point to Investing.com's broader financial news and market data platform, wit

Tone
Negative 42/100
Event
Market update
Published
27 Jun 2026 04:40
Source
Investing.com India
Investing.com Direct company coverage

Form 6K Immuron Ltd ADR For: 23 June

This article reports on the filing of Form 6K by Immuron Ltd ADR for June 23. It also includes standard disclaimers about the risks associated with trading financial instruments and cryptocurrencies, emphasizing the volatility and potential loss of investment. The content stresse

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 13:10
Source
Investing.com
Stock Titan Direct company coverage

Immuron (NASDAQ: IMRN) cancels 3.8M shares in small holder buy-back

Immuron Limited has completed a small holding share sale facility, buying back 3,805,528 ordinary shares at $0.032 per share, totaling $121,777. These shares will be cancelled, reducing the company's total shares on issue from 326,653,609 to 322,848,081 and decreasing the number

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 22:39
Source
Stock Titan
Stock Titan Direct company coverage

Immuron (NASDAQ: IMRN) reports expiry of 1.43M options and updated capital

Immuron Limited announced the expiry of 1.43 million IMCAI options listed on the ASX, which ceased on June 18, 2026, without being exercised or converted, and with no consideration paid. Following this, the company updated its issued capital to 326,653,609 ordinary fully paid sha

Tone
Neutral 50/100
Event
Market update
Published
19 Jun 2026 21:40
Source
Stock Titan
TradingKey Direct company coverage

Immuron Ltd (IMRN) Institutional Confidence

This article from TradingKey provides an overview of institutional confidence in Immuron Ltd (IMRN). It lists specific institutional shareholders, their shareholdings, and the percentage change in their positions. Key institutions like Morgan Stanley & Co. LLC and Citadel Advisor

Tone
Positive 68/100
Event
Market update
Published
17 Jun 2026 20:39
Source
TradingKey
TradingKey Direct company coverage

Immuron Ltd (IMRN) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Immuron Ltd (IMRN), detailing support and resistance levels, and analyzing various technical indicators and moving averages. As of the report, IMRN's technical indicators present a mixed signal with 1 buy and 2 sell signals, while mov

Tone
Negative 28/100
Event
Market update
Published
17 Jun 2026 10:10
Source
TradingKey
TradingKey Direct company coverage

Immuron Ltd (IMRN) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Immuron Ltd (IMRN), highlighting that one analyst rates the stock as a "Buy" with a target price of USD 5.00, representing a potential upside of 257.14%. The company's current stock price is 1.040 USD, with a market cap of 7.56M. The

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 07:40
Source
TradingKey
TradingKey Direct company coverage

Immuron Ltd (IMRN) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Immuron Ltd (IMRN)'s dividend and stock split history. It indicates that no dividends have been distributed in the past five years and there is no data available for past stock splits. The page serves as a data placeholder for these financial

Tone
Neutral 50/100
Event
Capital return
Published
17 Jun 2026 05:11
Source
TradingKey
TradingKey Direct company coverage

Immuron Ltd (IMRN) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Immuron Ltd (IMRN), listing its major shareholders and institutional holdings as of recent reporting periods. Key institutional investors include Morgan Stanley, Citadel Advisors, and XTX Markets, with updated statistics on shares

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 05:11
Source
TradingKey
TradingKey Direct company coverage

Immuron Ltd (IMRN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed revenue breakdown for Immuron Ltd (IMRN) as of July 6, 2023, showcasing its performance across different business segments and geographical regions. It highlights that the Travelan segment accounts for the vast majority of its revenue at 96.68%, w

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 04:11
Source
TradingKey
Kalkine Media Direct company coverage

Immuron (ASX: IMC): Advancing Gastrointestinal Product Portfolio Across Multiple Markets

Immuron Limited (ASX:IMC) (NASDAQ:IMRN) is actively expanding its gastrointestinal product portfolio and market presence, focusing on digestive health with products like Travelan® for travellers' diarrhoea and ProIBS® for IBS symptoms. The company reported a 16% increase in globa

Tone
Positive 72/100
Event
Market update
Published
02 Jun 2026 04:09
Source
Kalkine Media
Finviz Direct company coverage

IMRN - Immuron Limited ADR Stock Price and Quote

This article provides a detailed stock quote and company information for Immuron Limited (IMRN), an Australian biopharmaceutical company. It includes financial data, performance metrics, key ratios, and a comprehensive list of recent company news and events. The company focuses o

Tone
Positive 66/100
Event
Market update
Published
30 May 2026 13:12
Source
Finviz
Stock Titan Direct company coverage

Immuron (NASDAQ: IMRN) responds to ASX query on share price

Immuron Limited has filed a Form 6-K in response to an ASX price query regarding recent trading activity in its shares. The company stated it is not aware of any undisclosed information that would explain the movements and confirmed its compliance with ASX Listing Rule 3.1 on con

Tone
Neutral 50/100
Event
Market update
Published
28 May 2026 12:08
Source
Stock Titan
ChartMill Direct company coverage

IMRN Technical Analysis | Trend, Signals & Chart Patterns | IMMURON LTD-SPON ADR (NASDAQ:IMRN)

IMMURON LTD-SPON ADR (IMRN) has a strong technical rating of 8 out of 10, showing positive short-term trends and outperforming 85% of all stocks in the past year. However, its setup rating is low at 1 due to extended recent price rises, suggesting a wait for consolidation before

Tone
Neutral 50/100
Event
Analyst action
Published
27 May 2026 11:39
Source
ChartMill